Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.

@article{Dijkers2009DevelopmentAC,
  title={Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.},
  author={Eli C F Dijkers and Jos G. W. Kosterink and Anna P Rademaker and Lars Rutger Perk and Guus A. M. S. van Dongen and Joost Bart and Johan R. de Jong and Elisabeth G. E. de Vries and Marjolijn N. Lub-de Hooge},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2009},
  volume={50 6},
  pages={974-81}
}
UNLABELLED The anti-human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is administered to patients with HER2/neu-overexpressing breast cancer. Whole-body noninvasive HER2/neu scintigraphy could help to assess and quantify the HER2/neu expression of all lesions, including nonaccessible metastases. The aims of this study were to develop clinical-grade radiolabeled trastuzumab for clinical HER2/neu immunoPET scintigraphy, to improve diagnostic imaging, to guide antibody-based… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 92 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Characterization of 89Zrtrastuzumab for clinical HER2 immunoPET imaging [abstract

  • ECF Dijkers, MN Lub-De Hooge, JG Kosterink
  • J Clin Oncol
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…